HL: ICER analysis of brentuximab vedotin in first-line therapy

  • Huntington SF & al.
  • J Clin Oncol
  • 4 Oct 2018

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with newly diagnosed stage III/IV Hodgkin lymphoma (HL), treatment with AVD+BV (doxorubicin, vinblastine, and dacarbazine+brentuximab vedotin) was not cost-effective vs conventional treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

Why this matters

  • The most common first-line therapy for HL comprises ABVD; however, bleomycin has been associated with significant pulmonary toxicity.

Study design

  • Markov model analysis to compare the cost-effectiveness of AVD+BV vs ABVD in the treatment of patients with newly diagnosed HL.
  • Funding: Lowe Endowment Fund; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Science.

Key results

  • AVD+BV delivered an improvement of 0.56 quality-adjusted life years (QALYs) vs ABVD: 19.86 with AVD+BV vs 19.30 with ABVD.
  • Treatment with AVD+BV was associated with a $361,137 lifetime healthcare cost vs $184,291 with ABvd.
  • $317,254 per QALY incremental cost-effectiveness ratio for ABD + BV vs ABVD.

Limitations

  • Analysis was undertaken in the absence of long-term data for ABD +BV.  

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit